Philippe Rousselot, MD, PhD from Versailles Hospital and University, Versailles, France discusses the concern of molecular relapse in chronic myeloid leukemia (CML) patients. If therapy is stopped for patients in deep molecular response, despite being treated for years, approximately half of them will experience molecular relapse. This has been exemplified by the EURO-SKI study (NCT01596114). Prof. Rousselot focuses on the location of the cells that are responsible for those molecular relapses, and if they can be targeted. He goes on to discuss some of his own work targeting the expression of STAT5 in those cells, and the ability to erode them. Overall, he hopes to be able to accelerate this process to have a better status of remission and a lower rate of relapse after discontinuation of therapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.